Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

20.24USD
5:16pm GMT
Change (% chg)

$1.21 (+6.36%)
Prev Close
$19.03
Open
$19.00
Day's High
$20.24
Day's Low
$18.86
Volume
103,568
Avg. Vol
479,809
52-wk High
$21.95
52-wk Low
$4.33

Select another date:

Mon, Jan 8 2018

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

Select another date: